Antibiotik golongan tetrasiklina: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
Tidak ada ringkasan suntingan Tag: halaman dengan galat kutipan Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
Baris 18:
==Pemberian==
==Daftar Anggota==
{| class="wikitable sortable"
|-
! Antibiotik ([[Nama Generik Internasional|INN]])!! Sumber<ref name=Nelson/> !! Waktu paruh<ref>{{cite journal | vauthors = Agwuh KN, MacGowan A | title = Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines | journal = The Journal of Antimicrobial Chemotherapy | volume = 58 | issue = 2 | pages = 256–65 | date = August 2006 | pmid = 16816396 | doi = 10.1093/jac/dkl224 | doi-access = free }}</ref> !! Catatan
|-
| [[Tetrasiklin]] || rowspan=4|Naturally occurring || 6–8 jam (pendek) ||
|-
| [[Klortetrasiklin]] || 6–8 jam (pendek) ||
|-
| [[Oksitetrasiklin]] || 6–8 jam (pendek) ||
|-
| [[Demeklosiklin]] || 12 jam (menengah) ||
|-
| [[Limesiklin]] || rowspan=6| Semi-synthetic || 6–8 jam (pendek) ||
|-
| [[Meklosiklin]] || 6–8 jam (pendek) || (tidak lagi dipasarkan)
|-
| [[Metasiklin]] || 12 jam (menengah) ||
|-
| [[Minosiklin]] || 16+ jam (panjang) ||
|-
| [[Rolitetrasiklin]] || 6–8 jam (pendek) ||
|-
| [[Doksisiklin]] || 16+ jam (panjang) ||
|-
| [[Tigesiklin]] || Glycecyclines || 16+ jam (panjang) ||
|-
| [[Eravasiklin]] || rowspan=3|Newer || 16+ jam (panjang) || (formerly known as TP-434) received FDA approval on August 27, 2018, for treatment of complicated intra-abdominal infections.<ref>{{cite web|title=Drug Trial Snapshot: Xerava|url=https://www.fda.gov/Drugs/InformationOnDrugs/ucm620689.htm|publisher=FDA|access-date=2 October 2018}}</ref>
|-
| [[Saresiklin]] || 16+ jam (panjang) || (formerly known as WC 3035) received FDA approval on October 1, 2018, for treatment of moderate to severe [[acne vulgaris]].<ref>{{cite web|title=Drug Trial Snapshot: Seysara|url=https://www.fda.gov/Drugs/InformationOnDrugs/ucm623308.htm|publisher=FDA|access-date=8 February 2019}}</ref> Sarecycline is a [[Narrow-spectrum antibiotic|narrow-spectrum]] antibiotic.<ref>{{Cite web|work = PubChem|title=Sarecycline |url= https://pubchem.ncbi.nlm.nih.gov/compound/54681908 |access-date=2020-06-07| publisher = U.S. National Library of Medicine }}</ref><ref name="pmid30397052">{{cite journal | vauthors = Zhanel G, Critchley I, Lin LY, Alvandi N | title = Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris | journal = Antimicrobial Agents and Chemotherapy | volume = 63 | issue = 1 | date = January 2019 | pmid = 30397052 | pmc = 6325184 | doi = 10.1128/AAC.01297-18 }}</ref>
|-
| [[Omadasiklin]] || 16+ jam (panjang) || (formerly known as PTK-0796<ref>{{cite web|url=http://www.bioworld.com/content/antibiotic-firm-paratek-joins-ipo-queue-aiming-92m-0|title=Antibiotic Firm Paratek Joins IPO Queue; Aiming for $92M|access-date=13 March 2017|archive-date=18 October 2017|archive-url=https://web.archive.org/web/20171018072708/http://www.bioworld.com/content/antibiotic-firm-paratek-joins-ipo-queue-aiming-92m-0|url-status=dead}}</ref>) received [[FDA]] approval on October 2, 2018, for treatment of [[community-acquired pneumonia]]<ref>{{cite web|title=Drug Trial Snapshot: Nuzyra|url=https://www.fda.gov/Drugs/InformationOnDrugs/ucm624649.htm|publisher=FDA|access-date=8 February 2019}}</ref> and acute [[skin and skin structure infection]]s.<ref>{{cite web|title=Drug Trial Snapshot: Nuzyra|url=https://www.fda.gov/Drugs/InformationOnDrugs/ucm624630.htm|publisher=FDA|access-date=8 February 2019}}</ref>
|}
==Penggunaan sebagai Pereaksi dalam Penelitian==
| |||